BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1338 related articles for article (PubMed ID: 19497070)

  • 21. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases.
    Haque T; Chaggar T; Schafers J; Atkinson C; McAulay KA; Crawford DH
    J Med Virol; 2011 Feb; 83(2):311-6. PubMed ID: 21181928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients.
    Toyoda M; Moudgil A; Warady BA; Puliyanda DP; Jordan SC
    Pediatr Transplant; 2008 Nov; 12(7):778-84. PubMed ID: 18331541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.
    Weinstock DM; Ambrossi GG; Brennan C; Kiehn TE; Jakubowski A
    Bone Marrow Transplant; 2006 Mar; 37(6):539-46. PubMed ID: 16462755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of EBV-DNAemia by quantitative real-time PCR after adult liver transplantation.
    Loginov R; Aalto S; Piiparinen H; Halme L; Arola J; Hedman K; Höckerstedt K; Lautenschlager I
    J Clin Virol; 2006 Oct; 37(2):104-8. PubMed ID: 16931140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
    Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
    Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
    Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
    Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients.
    Scheenstra R; Verschuuren EA; de Haan A; Slooff MJ; The TH; Bijleveld CM; Verkade HJ
    Transpl Infect Dis; 2004 Mar; 6(1):15-22. PubMed ID: 15225222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction.
    Benden C; Aurora P; Burch M; Cubitt D; Lloyd C; Whitmore P; Neligan SL; Elliott MJ
    J Heart Lung Transplant; 2005 Dec; 24(12):2103-8. PubMed ID: 16364857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum Epstein-Barr virus DNA load in primary Epstein-Barr virus infection.
    Bauer CC; Aberle SW; Popow-Kraupp T; Kapitan M; Hofmann H; Puchhammer-Stöckl E
    J Med Virol; 2005 Jan; 75(1):54-8. PubMed ID: 15543583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
    Lee TC; Goss JA; Rooney CM; Heslop HE; Barshes NR; Caldwell YM; Gee AP; Scott JD; Savoldo B
    Clin Transplant; 2006; 20(6):689-94. PubMed ID: 17100717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients.
    Aalto SM; Juvonen E; Tarkkanen J; Volin L; Haario H; Ruutu T; Hedman K
    Clin Infect Dis; 2007 Nov; 45(10):1305-9. PubMed ID: 17968825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr viremia levels after pediatric liver transplantation as measured by real-time polymerase chain reaction.
    Kullberg-Lindh C; Ascher H; Saalman R; Olausson M; Lindh M
    Pediatr Transplant; 2006 Feb; 10(1):83-9. PubMed ID: 16499593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
    Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
    Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.